Skip to main content

ChEMBL_15 Released


We are pleased to announce the release of ChEMBL_15. This version of the database was prepared on 23rd January 2013 and contains:

1,434,432 compound records
1,254,575 compounds (of which 1,251,913 have mol files)
10,509,572 activities
679,259 assays
9,570 targets
48,735 documents
17 activity data sources

You can download the data from the ChEMBL ftpsite: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/latest/

Please see chembl_15_release_notes.txt for full details of all changes in this release, including important schema changes!


Data changes since the last release:
We have made several major changes/additions to the data in ChEMBL_15:

  • Incorporation of data from the USP Dictionary of USAN and International Drug Names.
  • Incorporation of monoclonal antibody clinical candidates and sequences.
  • Creation of targets for protein complexes and protein families.
  • Standardisation of activity data and identification of potential issues.
  • Annotation of predicted compound binding domains for subset of activity data.

These data sets are described in more detail in the release notes and will also be the subject of future blog posts. In addition, we have incorporated new data from the following sources:

  • Open TG-GATEs
  • TP-search transporter database
  • MMV Malaria Box screening data
  • GSK Tuberculosis screening data
  • GSK deposited supplementary data
  • DNDi Trypanosoma brucei screening data
  • Harvard malaria screening data
  • WHO-TDR malaria screening data


Database changes since the last release:
This release of ChEMBL contains major changes to the schema and data model, particularly around the representation of protein targets. 

Please see the release notes, ERD and schema documentation for more details of these changes. We will also run a series of webinars over the coming weeks, describing the new schema and the changes.


Interface changes since the last release:
New data tables have been introduced to display search results and bioactivity data. These tables allow users to customise the display and choose which columns they want to include. By default, a standard set of columns are included in the view, but additional columns can be added by clicking on the show/hide button above the table.

A BLAST search for biotherapeutic drugs has been included on the 'Ligand Search' tab (formerly 'compound search'), allowing retrieval of protein drugs by sequence similarity.

The 'Browse Drugs' tab now includes information for monoclonal antibody clinical candidates and compounds with USANs in addition to approved drugs. Additional fields have been added and drug icons have been divided into two sets representing structure-specific information (green) and product-specific information (blue) - the latter are shown only for approved drugs.

(btw the picture above is built from ChEMBL assay descriptions - thanks to George)



Comments

Popular posts from this blog

Improvements in SureChEMBL's chemistry search and adoption of RDKit

    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen

Improved querying for SureChEMBL

    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d